# NCT04965090 (NCT04965090)

> A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04965090
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Memorial Sloan Kettering Cancer Center
- Conditions: Metastatic Non Small Cell Lung Cancer; Recurrent Non Small Cell Lung Cancer
- Interventions: Amivantamab; Lazertinib
- Enrollment: 43
- Primary outcome: CNS overall response rate (ORR) (Cohort 1)
- Primary outcome: measure CNS overall response rate (ORR) (Cohort 2)

## Indexed commentary on NCT04965090 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct04965090